dihydroavenanthramide-d and Chronic-Disease

dihydroavenanthramide-d has been researched along with Chronic-Disease* in 1 studies

Other Studies

1 other study(ies) available for dihydroavenanthramide-d and Chronic-Disease

Article	Year
Dihydroavenanthramide D inhibits mast cell degranulation and exhibits anti-inflammatory effects through the activation of neurokinin-1 receptor. Experimental dermatology, 2017, Volume: 26, Issue:8 Chronic pruritus is difficult to treat. Current treatment options are frequently ineffective and new therapeutic approaches are urgently needed. Avenanthramides are active substances in oats that exhibit anti-inflammatory effects. Their potential to interrupt pruritus mechanisms was investigated in this study. It was found that the synthetic analog dihydroavenanthramide D (DHAvD) can interact with the neurokinin-1 receptor (NK1R) and inhibit mast cell degranulation. DHAvD also affects inflammatory processes and reduces secretion of the cytokine interleukin-6. Our findings indicate that DHAvD may act as a NK1R inhibitor and could be a promising candidate for topical treatments of chronic pruritus. Topics: Animals; Calcium Signaling; Cell Line; Chronic Disease; Drug Evaluation, Preclinical; Humans; Mast Cells; ortho-Aminobenzoates; Pruritus; Rats; Receptors, Neurokinin-1; Substance P	2017

Article

Year

Dihydroavenanthramide D inhibits mast cell degranulation and exhibits anti-inflammatory effects through the activation of neurokinin-1 receptor.

Experimental dermatology, 2017, Volume: 26, Issue:8

Chronic pruritus is difficult to treat. Current treatment options are frequently ineffective and new therapeutic approaches are urgently needed. Avenanthramides are active substances in oats that exhibit anti-inflammatory effects. Their potential to interrupt pruritus mechanisms was investigated in this study. It was found that the synthetic analog dihydroavenanthramide D (DHAvD) can interact with the neurokinin-1 receptor (NK1R) and inhibit mast cell degranulation. DHAvD also affects inflammatory processes and reduces secretion of the cytokine interleukin-6. Our findings indicate that DHAvD may act as a NK1R inhibitor and could be a promising candidate for topical treatments of chronic pruritus.

Topics: Animals; Calcium Signaling; Cell Line; Chronic Disease; Drug Evaluation, Preclinical; Humans; Mast Cells; ortho-Aminobenzoates; Pruritus; Rats; Receptors, Neurokinin-1; Substance P

2017